OQROStart free trial
Politician trade (House)

Amgen (AMGN): Rep. David J. Taylor (OH02) disclosed a purchase $1K–$15K

Rep. David J. Taylor (OH02) disclosed a purchase of Amgen in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
17 days
Disclosure lag
Traded
Jan 16, 2026
Disclosed
Feb 2, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 23, 2024CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  2. Nov 19, 2024CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  3. Nov 19, 2025FDAFDA drug approval: Imdelltra
  4. Nov 20, 2025Insider · 1 personInsiders: 2 sales (~$1.1M)
  5. Dec 3, 2025Congress · 1 personMembers of Congress: 2 sales
  6. Jan 16, 2026 · this disclosureCongressDisclosed purchase of AMGN — reported range $1,001 - $15,000

What came next

  1. Jan 29, 2026CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  2. Jan 30, 2026Company filing · Form 8-K · Agreement endedEnded an important agreement
  3. Feb 3, 2026Company filing · Form 8-K · ResultsReported its results
  4. Feb 17, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
  5. Feb 19, 2026InsiderOfficer sold ~$376K of AMGN shares in the open market
  6. Feb 26, 2026Insider · 1 personInsiders: 2 sales (~$20.8M)
  7. Feb 26, 2026CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  8. Mar 9, 2026Government · Federal Register noticeGranting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
  9. Mar 9, 2026Government · Federal Register noticeAspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
  10. Mar 24, 2026CongressDisclosed purchase of AMGN — reported range $15,001 - $50,000
  11. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  12. Mar 31, 2026Government · Federal Register proposed ruleFiduciary Duties in Selecting Designated Investment Alternatives
  13. Apr 17, 2026CongressDisclosed sale of AMGN — reported range $15,001 - $50,000
  14. Apr 22, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 22, 2026, Amgen Inc. (the “Company”) publicly announced that David M. Reese is retiring from the role of the Company’s Executive Vice President and Chief Technology Officer.”
  15. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  16. Apr 30, 2026Company filing · Form 8-K · ResultsReported its results
  17. Apr 30, 2026Government · Federal Register noticeChemoCentryx, Inc.; Proposal To Withdraw Approval of New Drug Application for TAVNEOS (Avacopan) Capsule, 10 Milligrams; Opportunity for a Hearing
  18. May 4, 2026InsiderOfficer sold ~$400K of AMGN shares in the open market
  19. May 14, 20265% stakeCapital World Investors reported a passive stake (13G) of 5.5%
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Amgen

For Amgen, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 54 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AMGN page.

Other recent filings by Rep. David J. Taylor (OH02)

The full history of Rep. David J. Taylor (OH02) is on the profile page.

How this filing works

Explore the data

Other disclosures at Amgen

Everything OQRO holds on this company is on its AMGN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Start free trialAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data